Side Branch Predilatation Strategy in Coronary Bifurcation Lesion Stenting (SBPS)
This study is currently recruiting participants.
Verified September 2011 by Medica Cor Heart Hospital
Sponsor:
Medica Cor Heart Hospital
Information provided by (Responsible Party):
Dobrin Vassilev MD, PhD, Medica Cor Heart Hospital
ClinicalTrials.gov Identifier:
NCT01430377
First received: September 3, 2011
Last updated: September 7, 2011
Last verified: September 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The role of Side Branch (SB) predilatation during coronary bifurcation lesion percutaneous coronary intervention (PCI) is still not established. The predilatation could potentially damage SB ostium by vessel dissection, making subsequent wiring problematic. However, predilatation could eliminate SB ostial stenosis obviating need for further SB treatment after main vessel stent implantation. The aim of the study is to assess in random fashion the periprocedural myonecrosis, complication rates and time for SB rewiring in groups with and without SB predilatation.
| Condition | Intervention | Phase |
|---|---|---|
|
Coronary Ostium Stenosis Myonecrosis |
Procedure: SB predilatation Procedure: No SB predilatation |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Side Branch Predilatation Strategy in Coronary Bifurcation Lesion Stenting (SBPS) |
Further study details as provided by Medica Cor Heart Hospital:
Primary Outcome Measures:
- Time for rewiring SB [ Time Frame: 24h ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Periprocedural myonecrosis [ Time Frame: 24 h ] [ Designated as safety issue: Yes ]
- MACE [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]death, MI, TVR
| Estimated Enrollment: | 120 |
| Study Start Date: | August 2011 |
| Estimated Study Completion Date: | May 2012 |
| Estimated Primary Completion Date: | April 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: SB predilatation |
Procedure: SB predilatation
Initial SB [predilatation.
Procedure: No SB predilatation
Without SB predilatation
|
Eligibility| Ages Eligible for Study: | 20 Years to 90 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria
- Subject at least 18 years of age.
- Subject able to verbally confirm understandings of risks, benefits of receiving PCI for true bifurcation lesions, and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure.
- Target main branch lesion(s) located in a native coronary artery with diameter of ≥ 2.5 mm and ≤ 4.5 mm. Target side branch lesion(s) located in a native coronary artery with diameter of ≥ 2.0 mm.
- Target lesion(s) amenable for PCI with balloon angioplasty of the side branch.
Exclusion Criteria
- ST-segment elevation myocardial infarction (STEMI)
- Non-cardiac co-morbid conditions are present with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment).
- Subjects who refuse to give informed consent.
- Subjects with left ventricle ejection fraction <30%
- Subjects with moderate or severe degree valvular heart disease or primary cardiomyopathy
- Contraindications for 12 months double antiplatelet therapy
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01430377
Contacts
| Contact: Dobrin I Vassilev, MD, PhD | 00359886846550 | dobrinv@gmail.com |
Locations
| Bulgaria | |
| Medica Cor Heart Hospital | Recruiting |
| Ruse, Bulgaria, 7000 | |
| Contact: Dobrin I Vassilev, MD, PhD 00359886846550 dobrinv@gmail.com | |
| Contact: Hristo Popov, MD 00359887686003 hrpopov@gmail.com | |
Sponsors and Collaborators
Medica Cor Heart Hospital
More Information
No publications provided
| Responsible Party: | Dobrin Vassilev MD, PhD, Medica Cor Heart Hospital |
| ClinicalTrials.gov Identifier: | NCT01430377 History of Changes |
| Other Study ID Numbers: | SBPS |
| Study First Received: | September 3, 2011 |
| Last Updated: | September 7, 2011 |
| Health Authority: | Bulgaria: Ethics commettee |
Keywords provided by Medica Cor Heart Hospital:
|
periprocedural myonecrosis procedure time fluoroscopy time |
ClinicalTrials.gov processed this record on June 17, 2013